
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This trial looked at combining eltrombopag with azacitidine for people with myelodysplastic syndrome (MDS).
This trial was open for people to join between 2014 and 2018. The team reported the results in 2021.
Doctors can treat myelodysplastic syndrome (MDS) with azacitidine. This works but doctors are always looking for ways to improve treatment.
Eltrombopag is a drug that increases the number of cells called in your blood. We knew from research that a drug like eltrombopag taken with azacitidine helped people with MDS.
The researchers wanted to find out if eltrombopag taken with azacitidine can do the same. To do this, they first needed to find the best dose to give.
The main aims of this trial were to find out:
The team found the best dose of eltrombopag to give with azacitidine.
Trial design
This was a study. Everyone had eltrombopag. 31 people took part.
The first few people had a low dose of eltrombopag with azacitidine. If they didn’t have any serious side effects, the next few people had a higher dose. And so on, until they found the best dose to give.
Results
Overall 17 people of the 31 people completed their treatment of eltrombopag and azacitidine. And 14 people didn’t.
Reasons for not completing the treatment were:
The team found that they could increase the dose of eltrombopag to the highest one without any of the side effects becoming too bad.
Side effects
The side effects reported most often were:
Conclusion
The team concluded that the combination of eltrombopag and azacitidine was safe and acceptable.
They noted that a large looked at this combination and found some concerns about how safe it is and how well it works. Their conclusion was it shouldn’t be
for people with MDS.
Where this information comes from
We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently () or published in a medical journal yet. The figures we quote above were provided by the research team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Alex Sternberg
Blood Cancer UK
Celgene
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Novartis
University of Birmingham
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.